Brussels, 30/09/2009 (Agence Europe) - Following the positive scientific opinion issued by the European Medicines Agency (EMEA), on 24 September, the European Commission authorised the marketing of the first two vaccines for the H1N1 strain of the flu virus, one from Swiss laboratory Novartis (vaccine called Focetria) and the other from the UK lab GlaxoSmithKline (Pandemrix), the Commission has announced in a press release. The vaccines will be authorised for use in all member states of the...